The Rationale for Bemcentinib Plus Pembrolizumab in AXL-Positive NSCLC
February 11th 2020Matthew Krebs, MBChB, PhD, explains the rationale for a phase II study of bemcentinib, a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced non–small cell lung cancer, which he presented at the 2019 Society for Immunotherapy of Cancer Annual Meeting.
Watch
Rationalizing the Study of Intratumoral Immunotherapy in Breast Cancer Origin Liver Metastases
February 5th 2020Jason Williams, MD, the director of Interventional Oncology and Immunotherapy oncologist at the Williams Cancer Institute, discusses a study in which an immunotherapy combination was administered intratumorally to patients with liver metastases linked to breast cancer, which he presented in a poster at the 2019 Society of Immunotherapy of Cancer Annual Meeting.
Watch
Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCC
February 4th 2020Peter R. Galle, MD, discusses the findings that came from the phase III IMbrave 150 clinical trial, which evaluated the combination of atezolizumab plus bevacizumab versus the standard of care, sorafenib, as frontline treatment of patients with unresectable hepatocellular carcinoma.
Watch
PARP Inhibitors Advance Beyond Treatment of BRCA1/2-Mutant Gynecologic Cancers
February 4th 2020Mira Hellmann, MD, discusses how the use of PARP inhibitors as treatment of patients with gynecologic cancers has evolved since they were first introduced into the treatment landscape up to studies evaluating these therapies today in a variety of patient populations, particularly in patients with ovarian cancer.
Watch
Addressing the Role of Consolidation Immunotherapy in Patients With Lung Cancer
February 4th 2020Nasser H. Hanna, MD, discusses the key takeaways on the current role of consolidation immunotherapy in patients with lung cancer, which has become standard in this setting. He highlights questions that still need to be addressed in this space.
Watch
Exploring FDA-Approved Therapies for Nonmetastatic Castration-Resistant Prostate Cancer
January 31st 2020A. Oliver Sartor, MD, discusses the current treatment options for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and what physicians should consider when selecting treatment for their patients.
Watch